Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue, studied for its potential to stimulate endogenous growth hormone release through selective receptor interaction. It functions by binding to the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, in the pituitary and hypothalamus.

Preclinical research suggests that Ipamorelin may promote pulsatile growth hormone secretion without significantly influencing other pituitary hormones in experimental models. These receptor-mediated mechanisms are believed to underlie its observed effects in studies examining endocrine signaling, metabolic regulation, and tissue repair–associated pathways. Because it stimulates natural hormone release rather than supplying exogenous hormone, it has been investigated as a tool for evaluating physiologic growth hormone dynamics.

Beyond growth hormone signaling, Ipamorelin has also been explored for its potential influence on sleep-related pathways, recovery processes, and metabolic balance due to its interaction with ghrelin-associated signaling networks. Ongoing research continues to evaluate its impact on hormonal modulation, adaptive physiology, and systemic metabolic regulation.